In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

G. Metro

Z. ZhengDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida,

A. FabiMedical Oncology, Regina Elena Cancer Institute, Rome, Italy,

M. SchellDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida,

B. AntonianiDepartment of Pathology, Regina Elena Cancer Institute, Rome, Italy,

M. MottoleseDepartment of Pathology, Regina Elena Cancer Institute, Rome, Italy,

A. N. MonteiroDepartment of Risk Assessment, Detection and Intervention, Moffitt Cancer Center, Tampa, Florida,

P. ViciMedical Oncology, Regina Elena Cancer Institute, Rome, Italy,

S. Lara RiveraInternal Medicine, University of South Florida, Tampa, Florida

D. BoulwareDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida,

F. CognettiMedical Oncology, Regina Elena Cancer Institute, Rome, Italy,

G. BeplerDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida,

show all

ABSTRACT

Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-small-cell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6–2774.1, 74.0–410.3, and 54.4–1833.1, respectively. They were significantly associated with each other (Spearman's rho ⩾ .36; p⩽ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

Information for

Open access

Opportunities

Help and information

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature